Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Press Release


Japanese Pharmaceutical Market Set to Grow 3.3% (CAGR) Between 2017 and 2022, Significantly Lower than the Worldwide Outlook (6.5% CAGR)

Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement

Download PDF

LONDON, BOSTON, TOKYO (August 1, 2017) — According to life science commercial intelligence firm, Evaluate, the enforcement of a much more stringent pricing revision policy in Japan, both for new products as well as off-patent brands, is behind the decline of the products currently on the market which are forecast to drop about 2% annually in sales through 2022.

The prices of Gilead’s hepatitis C virus (HCV) blockbusters Sovaldi and Harvoni have been subject to significant price scrutiny and most recently the Japanese government has forced a price reduction of 50% on Opdivo, BMS’ novel PD-1/PD-L1 agent.

However, the sales decline of marketed products is counterbalanced by the optimism surrounding new therapies coming to market expected to account for 34% of sales in 2022, among the top ranking are Dupixent (Sanofi), Ibrance (Pfizer), Entresto (Novartis), Aducanumab (Biogen), and Emicizumab (Chugai).

Evaluate recently launched consensus drug forecasts for the Japanese market revealing new insights on the future outlook of the country’s Pharma & Biotech sector for benchmarking and market analysis. For more information and to download the topline marketed and R&D forecast to 2022 in Yen and USD visit: www.evaluate.com/Japan-Drug-Forecasts-2017.

About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2022. Our subscription services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Evaluate's Custom Services provide project-based analytical and data services. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving your daily opinion and insights. The Evaluate service enable the life science community to make sound business decisions about value and opportunity.

For more information visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epclinicaltrial, @epvantage.

Back to Press Releases